Roger Jeffs

Chief Executive Officer, Liquidia

Search every verified Roger Jeffs interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Roger Jeffs, Chief Executive Officer of Liquidia, discussed the company’s initial commercial launch of Yutrepia during the second quarter 2025 earnings call. He reported that within 11 weeks of approval, the company had shipped product and supported physicians, with specialty pharmacies reporting over 900 unique patient prescriptions and more than 550 patient starts. Jeffs described the pace of adoption as unprecedented in the prostacyclin space and attributed it to the product’s deep lung delivery and low-effort device. He also noted the company’s focus on expanding payer access and preparing for a research and development day for L606 in the fall. On the third quarter 2024 earnings call, Jeffs stated that the company had a clear path to seeking final approval of Yutrepia for both pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, potentially following the expiration of Tyvaso DPI’s clinical exclusivity in May 2025. He highlighted FDA confirmation that the amended new drug application to add PH to the tentatively approved label was proper. Jeffs also indicated that upcoming data would differentiate Yutrepia’s value, particularly regarding dosing, speed to effective dose, clinical outcomes, and treatment persistence and durability.